SOLICITATION NOTICE
B -- RNA Extraction from Tempus Blood Tubes
- Notice Date
- 9/18/2013
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-(HG)-2013-311-DLM
- Archive Date
- 10/8/2013
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- i. "This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued." ii. The solicitation number is HHS-NIH-NHLBI-CSB-(HG)-2013-311-DLM and the solicitation is being posted as a request for proposal (RFP). iii. The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-69, September 3, 2013. iv. There are no set-aside restrictions, the associated NAICS code is 541711 Research and Development in Biotechnology and the small business size standard is 500 employees. The acquisition is being conducted in accordance with the procedures of FAR Part 12 and FAR Part 13. This requirement is under the Simplified Acquisition Threshold (SAT) of $150,000.00. v. Purchase Order line items : 1. RNA Extraction from Tempus Blood Tubes using MagMax for Stabilized Blood Tubes using RNA Isolation Kit: Product (http://products.invitrogen.com/ivgn/product/4451893) NOTE: RNA extraction needs to be performed by a human operator; 2. Globin Reduction using Invitrogen GlobinClear Kit; 3. RIN/RNA analysis on Agilent Bioanalyzer RNA Nano Chips; and 4. Aliquoting [three Eppendorf Biopur 1.5 mL tubes] vi. Background : The National Institute of Health (NIH) is the nation's leading medical research agency and the primary Federal agency mission to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability.conducting, supporting and making medical discoveries that improve people's health and save lives. The National Human Genome Research Institute (NHGRI) is the premier federal government research institution conducting research into the genetic basis of human disease. The laboratory of Dr. Gary Gibbons, administratively housed within NHGRI's Division of Intramural Research, conducts a wide portfolio of clinical research addressing the issue of minority health disparities, especially as they pertain to cardiovascular disease. Objectives : Next-generation DNA sequencing (NGS) is rapidly changing the world of clinical genomics research. The power of NGS lies in its ability to discover new genetic variation that may be related to disease, as compared to older technologies like genome-wide association and expression microarrays that were constrained to the study of previously known variants. The Gibbons laboratory proposes to apply NGS as a powerful new tool for studying minority health disparities in cardiovascular disease (with an initial focus on resistant hypertension). As a starting point, we plan to conduct RNA-Seq experiments on blood samples from a clinically well-characterized African-American cohort. For this experiment, we require RNA extraction services from clinical blood samples. Contractor Requirements : Specific Tasks : 1. The Contractor shall provide high quality total RNA isolated from human blood. 2. The contractor shall perform globin depletion on the total RNA 3. The Contractor shall provide state-of-the art RNA quality control on the Agilent BioAnalyzer 2100 platform using the RNA Nano 6000 kit. 4. The contractor shall aliquot the extracted and globin-depleted RNA into three separate tubes with specified amounts in each tube viii. The FAR Provision 52.212-1, Instructions to Offerors -- Commercial, applies to this acquisition and is hereby incorporated by reference. All Federal Acquisition Regulations (FAR) clauses may be viewed at http://acquisition.gov/comp/far/index.html. The proposal must reference the RFP Number: HHS-NIH-NHLBI-CSB-(HG)-2013-311-DLM. All responsible offerors may submit a proposal, which if timely received, shall be considered by the agency. All proposals shall contain the following : 1. Name of Contracting Organization; 2. Solicitation number; 3. Contract Type; 4. Total Contract Value and Discounts; 5. Description of Requirement; 6. North American Industry Classification System (NAICS) Code; and 7. DUNS Number. ix. In accordance to FAR clause 52.212-2, Evaluation - Commercial Items The Government will award a Purchase Order resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate offers: Evaluation Factors (100 Points): 1. Manual RNA extraction from peripheral blood in 200 TempusTM tubes (30 Points) 2. Prior experience with handling cardiovascular disease blood samples (30 Points) 3. Globin reduction using Ambion GlobinClear kit (20 Points) 4. RNA QC using Agilent BioAnalyzer RNA6000 Nano chips (10 Points) 5. Aliquoting into tubes with 1 microgram amounts (10 Points) Price (This will be Firm-Fixed Price): An evaluation of the offeror's price proposal will be made to determine if proposed prices are realistic for the work to be performed, reflect a clear understanding of the requirements, and are consistent with the technical proposal. x. In accordance with FAR Clause 52.212-3, Offeror Representations and Certifications - Commercial Items, offerors must complete annual representations and certifications on-line at https://www.sam.gov/portal/public/SAM/. xi. FAR clause 52.212-4, Contract Terms and Conditions - Commercial Items applies to this acquisition. xii. FAR clause 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items applies to this Acquisition. Additional FAR Clauses include: FAR clause 52.204-10, Reporting Executive Compensation and First-Tier Subcontract Awards (JUL2013) (Pub.L. 109-282) (31 U.S.C. 6101 note). FAR clause 52.223-18, Encouraging Contractor Policies to Ban Text Messaging while Driving (AUG2011). FAR clause 52.225-13, Restrictions on Certain Foreign Purchases (JUN 2008) (E.O.'s, proclamations, and statutes administered by the Office of Foreign Assets Control of the Department of the Treasury). FAR clause 52.232-33, Payment by Electronic Funds Transfer-System for Award Management (JUL2013) (31 U.S.C. 3332). xiii. There are no additional contract requirement(s) or terms and conditions (such as contract financing arrangements or warranty requirements) determined by the contracting officer to be necessary for this acquisition and consistent with customary commercial practices. xiv. The Defense Priorities and Allocations System (DPAS) and assigned rating does not apply to this acquisition. xvi. All responsible offerors may submit a proposal, which if timely received, shall be considered by the agency. Offers are due by 12 Noon (EST) on September 23, 2013. Proposals shall be emailed to the Contracting Specialist, Dorothy Maxwell at maxwelld@nhlbi.nih.gov; Faxed proposals will NOT be accepted.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-(HG)-2013-311-DLM/listing.html)
- Place of Performance
- Address: NIH, 10 Center Drive, Building 10, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN03192927-W 20130920/130918235120-a6683e1c78be60221ea06a5e178380d9 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |